Interestingly, the combination of HU5F9-G4 with cetuximab or panitumumab (anti-EGFR mAbs) reduces tumor burden more than any of the monotherapies in immunodeficient mice harboring patient-derived xenografts [53]. Here, EGFR is linked to neoplasm.